Abstract Details

Title Digital Performance Measures Show Sensitivity to Demographic and Disease Characteristics in a Multiple Sclerosis Cohort Utilizing the MS Care Connect Mobile App in a Real-world Setting

Topic Multiple Sclerosis

Presentation(s) P18 - Poster Session 18 (5:30 PM-6:30 PM)

Poster/Presentation
Number 12-004

Background Functional health assessments for PwMS include walking speed, upper motor functioning, vision, and cognitive functioning. These assessments are difficult to conduct efficiently and frequently in the clinic setting. Digitized versions of traditional tests using mobile app technology can be self-administered to provide frequent, standardized data.

Objective To evaluate results from a multi-dimensional suite of performance measures self-administered in a real-world setting via a mobile app by people with multiple sclerosis (PwMS), and examine their relationship to demographic and disease characteristics as well as patient-reported outcome surveys (PROs).

Design/Methods MS Care Connect (MSCC) is a freely available mobile app for PwMS which includes several cognitive tests, the timed 25-foot walk (T25FWT), finger tapping (FTT), and color vision (CVT) tests, as well as PROs on health-related quality of life. Test scores (n=158-892) were assessed in relation to demographic and disease variables, and convergent validity was evaluated by examining relationships to scores of corresponding PROs.

Results Poorer cognitive performance was associated with older age (|r|=0.12-0.46; p <0.001-0.006), as was performance on the FTT (r= -0.24; p<0.001) and CVT (rho= -0.10; p=0.009), but not the T25FWT. Poorer scores were associated with advanced patient-determined disease steps (PDDS) for all tests (|rho|=0.22-0.44; p< 0.001). All measures differentiated employment status (disabled versus working full-time; p<0.001), and most differentiated MS subtype (relapsing-remitting versus progressive forms; p < 0.001-0.012). Cognitive tests correlated with the cognition PRO (p<0.001; |r|=0.16-0.46), as did the FTT with upper extremity functioning (p<0.001; r=0.37), the T25FWT with mobility (p<0.001; r=-0.46), and the CVT with vision impairment (p<0.001; r=-0.22) PROs. The CVT demonstrated higher prevalence of bilateral dyschromatopsia in males (p<0.001), and no gender difference for unilateral dyschromatopsia.

Conclusions Self-administered performance assessments conducted via the MSCC mobile app in a real-world setting exhibit sensitivity to functional health status, and may provide clinical utility in the management of MS.

Authors/Disclosures
Ryan Metzger, PhD (RM Biosciences) PRESENTER	An immediate family member of Dr. Metzger has received personal compensation for serving as an employee of Neurocrine Biosciences. Dr. Metzger has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Interpro Bioscience. An immediate family member of Dr. Metzger has stock in Ascendis. An immediate family member of Dr. Metzger has stock in Neurocrine Biosciences.
	No disclosure on file
Angelene Christensen (Rocky Mountain MS Research Group)	Ms. Christensen has a non-compensated relationship as a project manager with InterPro Bioscience that is relevant to AAN interests or activities.
John F. Foley, MD, FAAN (Rocky Mountain MS Clinic)	The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave. Dr. Foley has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for TG Therapeutics . The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics. The institution of Dr. Foley has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Foley has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Foley has stock in InterPRO Bioscience. The institution of Dr. Foley has received research support from Biogen. The institution of Dr. Foley has received research support from Novartis. The institution of Dr. Foley has received research support from Octave. The institution of Dr. Foley has received research support from Genentech. The institution of Dr. Foley has received research support from Imstem. The institution of Dr. Foley has received research support from Aegir.